Claims
- 1. A compound having Formula II: (SEQ ID NO: 13488)
5′-usascs asau ucU GAu Gag gcg aaa gcc Gaa Aag aca aB-3′ wherein each a is 2′-O-methyl adenosine nucleotide, each g is a 2′-O-methyl guanosine nucleotide, each c is a 2′-O-methyl cytidine nucleotide, each u is a 2′-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2′-deoxy-2′-C-allyl uridine, and B is an inverted deoxyabasic moiety.
- 2. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 3. A method of administering to a cell the compound of claim 1 comprising contacting said cell with the compound under conditions suitable for said administration.
- 4. The method of claim 3, wherein said cell is a mammalian cell.
- 5. The method of claim 3, wherein said cell is a human cell.
- 6. The method of claim 3, wherein said administration is in the presence of a delivery reagent.
- 7. The method of claim 6, wherein said delivery reagent is a lipid.
- 8. The method of claim 7, wherein said lipid is a cationic lipid.
- 9. The method of claim 7, wherein said lipid is a phospholipid.
- 10. The method of claim 6, wherein said delivery reagent is a liposome.
- 11. A method of administering to a cell the compound of claim 1 in conjunction with one or more other known drugs comprising contacting said cell with the compound and the other known drug under conditions suitable for said administration.
- 12. A method of inhibiting ocular angiogenesis in a patient comprising the step of contacting said patient with the compound of claim 1 under conditions suitable for said inhibition.
- 13. The method of claim 11, wherein said angiogenesis is associated with diabetic retinopathy.
- 14. The method of claim 11, wherein said angiogenesis is associated with age related diabetic retinopathy.
- 15. A method of cleaving RNA comprising a sequence of KDR RNA comprising contacting the compound of claim 1 with said RNA under conditions suitable for the cleavage of said RNA.
- 16. The method of claim 14, wherein said cleavage is carried out in the presence of a divalent cation.
- 17. The method of claim 15, wherein said divalent cation is Mg2+.
- 18. A method of administering to a mammal the compound of claim 1 comprising contacting said mammal with the compound under conditions suitable for said administration.
- 19. The method of claim 17, wherein said mammal is a human.
- 20. The method of claim 17 wherein said administration is in the presence of a delivery reagent.
- 21. The method of claim 17, wherein said delivery reagent is a lipid.
- 22. The method of claim 20, wherein said lipid is a cationic lipid.
- 23. The method of claim 20, wherein said lipid is a phospholipid.
- 24. The method of claim 19, wherein said delivery reagent is a liposome.
Parent Case Info
[0001] This patent application is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/870,161, filed May 29, 2001, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/708,690, filed Nov. 7, 2000, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/371,722, filed Aug. 10, 1999, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 08/584,040, filed Jan. 11, 1996, which claims the benefit of Pavco et al., U.S. S No. 60/005,974, filed on Oct. 26, 1995, all of these earlier applications are entitled “Method and Reagent for Treatment of Diseases or Conditions Related To Levels of Vascular Endothelial Growth Factor Receptor”. Each of these applications is hereby incorporated by reference herein in its entirety including the drawings and tables.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60005974 |
Oct 1995 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09870161 |
May 2001 |
US |
Child |
10138674 |
May 2002 |
US |
Parent |
09708690 |
Nov 2000 |
US |
Child |
09870161 |
May 2001 |
US |
Parent |
09371722 |
Aug 1999 |
US |
Child |
09708690 |
Nov 2000 |
US |
Parent |
08584040 |
Jan 1996 |
US |
Child |
09371722 |
Aug 1999 |
US |